Related Experiment Video
Updated: Nov 6, 2025

02:22
Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
Published on: April 12, 2024
596
Hypothalamic Pilomyxoid Astrocytoma in a Child with Lipodystrophy
J C Benson1, J Trejo-Lopez2, S E Bach3
1Department of Radiology (J.C.B., T.J.K., L.E., J.G.), Mayo Clinic, Rochester, Minnesota benson.john3@mayo.edu.
AJNR. American Journal of Neuroradiology
|May 7, 2021
Summary
Pilomyxoid astrocytomas are rare pediatric brain tumors with aggressive tendencies. Imaging features like homogeneous enhancement can suggest this diagnosis, differentiating it from pilocytic astrocytomas.
Area of Science:
- Pediatric neuro-oncology
- Neuroradiology
- Pediatric neuropathology
Background:
- Pilomyxoid astrocytoma (PMA) is a rare pediatric central nervous system (CNS) malignancy, distinct from pilocytic astrocytoma (PA).
- PMAs exhibit more aggressive behavior and a higher risk of leptomeningeal spread compared to PAs.
- Classification by the World Health Organization in 2007 highlighted the need for accurate differentiation.
Observation:
- A case of a hypothalamic pilomyxoid astrocytoma presenting with profound generalized lipodystrophy is described.
- Imaging findings suggestive of PMA include homogeneous enhancement, leptomeningeal seeding, and absence of intratumoral cysts.
- Histologic features include an angiocentric cellular arrangement and a myxoid background.
Findings:
- While definitive diagnosis requires tissue sampling, specific imaging characteristics can aid in suspecting PMA.
- Understanding these imaging and pathological features is crucial for early identification and management.
- The distinct clinical presentation in this case underscores the varied manifestations of pediatric brain tumors.
Implications:
- Improved diagnostic accuracy through recognition of imaging and pathological hallmarks of PMA.
- Timely and appropriate treatment strategies for pediatric CNS malignancies.
- Further research into the pathogenesis and clinical behavior of pilomyxoid astrocytomas.
Related Concept Videos
Hypoglycemia and Glucagon
503
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
503
Lysosomal Hydrolases
4.2K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.2K
Overview of Lipid Metabolism
3.5K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
3.5K

